IMPORTANCE Approximately 4% to 5% of breast cancer survivors will develop a new ipsilateral or contralateral cancer (in-breast event) over the 5 years following diagnosis, and annual surveillance mammography is recommended for those with residual breast tissue. The risk for such in-breast events persists over time, though increasing age at cancer diagnosis and treatment with hormonal therapy are associated with lower risk, and most older survivors of breast cancer will ultimately die from nonbreast cancer-related causes. Specific guidelines for surveillance strategies in older patients are limited. Prospective data on the benefits and harms of surveillance mammography in this population are lacking, and most of the evidence is derived from observational, retrospective data, often in the general population.
those 70 years or older, the probability of developing breast cancer over the next 10 years is 1 of 27 (3.7%). 2 Although most breast cancers in older women are lower-risk and most older patients with breast cancer die of other causes, [3] [4] [5] approximately 47% of all annual US breast cancer deaths occur in women age 70 years or older. 6 Past recommendations for annual screening mammography have been recently challenged by significantly revised national guidelines. The American Cancer Society (ACS) 7 and the United
States Preventative Services Task Force (USPSTF) 8 now recommend biennial screening for average-risk women and encourage individualized, shared decisions about when to begin screening and at what frequency. Clear guidance is lacking regarding decisions about screening for older women, largely because of a lack of prospective data on how mammography impacts breast cancer mortality in this population. Even fewer data are available to guide recommendations on surveillance mammography for older survivors of breast cancer. This is particularly problematic for clinicians caring for an aging US population with increasing numbers of older patients who will develop cancer. 9 Once a breast cancer is diagnosed, current guidelines encourage annual surveillance mammography for all patients with residual breast tissue and do not specifically tailor follow-up strategies. Furthermore, studies have consistently shown that the risk of second breast cancer events in survivors does not plateau with time, suggesting that there may be an indefinite benefit of mammography. 10, 11 Explicit guidance on how to approach surveillance in older or frail breast cancer survivors is lacking, and the limited data regarding surveillance in older cancer survivors across all cancers is now widely recognized as a significant research gap and priority. 12 We review existing guidelines for breast cancer screening and surveillance for older women, the risks for subsequent ipsilateral or contralateral cancers (in-breast events) in older survivors of breast cancer, and the expected benefits and risks of surveillance mammography. In this context, we propose potential alternative surveillance strategies for older breast cancer survivors.
Recommendations for Mammographic Screening in Older Women
The primary benefit of screening is a reduction in breast cancer mortality, estimated to be between 14% and 33% for women ages 50 to 74 years, with minimal data available to guide screening in women 75 years or older. 7, 8, [13] [14] [15] The most recent screening recommendations ( Table 1 ) have aimed to better reflect and balance the potential benefits and harms of screening mammography with maximization of improvements in breast cancer mortality and minimization of the risks of screening. 16, 17 These recommendations recognize the value of screening programs but also the importance of a personalized approach that incorporates a woman's cancer risk, as well as her preferences regarding the relative benefits and harms of screening. 16, 26 The benefits of mammography are strongly correlated with age, and women ages 50 to 69 years benefit the most 15 [27] [28] [29] [30] [31] [32] It is at the extremes of age where the harms may be greatest and benefits the least, for whom the balance of risk-to-benefit is unknown, and where the guidelines provide limited direction. Current breast cancer screening guidelines for older women are conflicting. The USPSTF states that for women 75 years or older, "current evidence is insufficient to assess the balance of benefits and harms of screening." 8 This lack of clarity is largely based on the limited numbers of women older than 70 years in screening studies, 33 and the nonsignificant reduction in breast cancer mortality with mammography among these women. No randomized clinical trials in screening populations have included women 75 years or older. The National Comprehensive Cancer Network (NCCN) recommends annual screening mammography for most women, specifically stating that "with the high incidence of breast cancer in the elderly population, the same screening guidelines used for women who are 40 years and older are recommended. Clinicians should always use judgment when applying screening guidelines." 18 The evidence for screening mammography in older women was thoughtfully reviewed by Walter and Schonberg, 34 who concluded: "For women with less than a 10-year life expectancy, recommendations to stop screening mammography should be framed around increased harms and the need to refocus health promotion on interventions likely to be beneficial over a shorter timeframe. For women with life expectancy of between 5 and 10 years, the decision about whether potential benefits of screening outweigh harms is a value judgment that requires a realistic understanding of screening outcomes." 34(p1336) The newest guidelines from the ACS have provided similar guidance regarding cessation of screening, stating 7(p1610) : "women 55 years and older should transition to biennial screening...women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer." 17 
Recommendations for Surveillance Mammography in Older Survivors of Breast Cancer
The ACS and American Society of Clinical Oncology (ASCO) recommend annual mammography in all breast cancer survivors with residual breast tissue. 25 For older patients, these recommendations lack information regarding the balance of harms and benefits of surveillance mammography; the number of false positives is less well defined than in screening populations and may be underemphasized in practice owing to concerns for higher risk of second breast cancers and local recurrences. Recently revised Older Adult Oncology NCCN guidelines address surveillance in older survivors of breast cancer, noting that decisions should be based primarily on patient preference and life expectancy, promoting routine calculation of estimated life expectancy to inform decisions ( Table 2) . 24,36 As a result, there is variability in the rates of surveillance mammograms in older survivors of breast cancer, 37, 38 with receipt occurring more frequently for those having regular follow-up with providers. 38 
Risk of In-Breast Events in Older Survivors of Breast Cancer
The goal of surveillance mammography is to detect new, early-stage, or recurrent cancers that would affect a woman's longevity. To calculate the benefits of surveillance mammography in older patients, it is useful to first consider the risks for bilateral, in-breast events in older survivors of breast cancer with residual breast tissue.
Risk for Ipsilateral Recurrence in Those Undergoing Breast Conservation
Although the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 39 reported an overall risk for distant or local recurrence for breast conservation (BCS)-only-treated patients at 10 years of 35.0% compared with 19.7% in those receiving BCS with radiation, recurrences decreased with increasing age and with estrogen receptor (ER)-positive disease. In women ages 60 to 69 years and 70 years or older, the 10-year risk of locoregional or distant recurrence for those receiving radiation was 14.2% and 8.8%, respectively (vs 36.1% for women 40 years or younger). 39 Rates of recurrence in the EBCTCG analysis were further lowered by the use of endocrine therapy and chemotherapy, although interpretations are limited because local and metastatic recurrences were reported together. 39 For women with ER-positive disease taking tamoxifen in the EBCTCG analysis, the 10-year risk of locoregional or distant recurrence was 8.7% in radiation-treated patients and 22.0% in BCSonly treated patients, whereas rates of recurrence with and without radiation for those with ER-poor disease were 28.9% and 43.8%, respectively, suggesting the importance of tumor biology when calculating ipsilateral recurrence risk. 39 Furthermore, in a single institution study, at 6 years of follow-up, 7% of women with triple negative or basal tumors developed ipsilateral recurrences compared with 0.8% of those with luminal A cancers (ER/progesterone receptor positive, low grade, and most frequently seen in older patients). 40 This is consistent with data from Liu et al 41 suggesting that omission of radiation is safe in those with luminal A cancers because of a 1.3% risk for in-breast recurrence with tamoxifen alone. The timing of ipsilateral breast events is also influenced by biology, with a shorter time-to-local-recurrence for those with triple negative disease vs other tumors. 42 For example, compared with women who have ER-positive tumors, the risk of a recurrence is lower for women with triple-negative disease who have not developed a recurrence by 5 to 10 years diagnosis. This is consistent with evidence from Cancer and Leukemia Group B Trial 9343, where 0.6% of women 70 years and older receiving radiation and tamoxifen developed isolated in-breast recurrences, compared with 6% of women who received tamoxifen alone. On this trial, an additional 6 patients (1.9%) developed axillary recurrences in the tamoxifen-only arm compared with 0% of patients receiving both radiation and tamoxifen. 49, 50 Similarly, data from the PRIME II trial that examined BCS with or without radiation in patients 65 years or older receiving hormonal therapy demonstrated local recurrences of less than 5% in both groups at a median follow-up of 5 years and no differences in distant recurrences or survival. 51 Certainly, these studies suggest that the vast majority of older patients with low-risk cancers will have a risk of ipsilateral recurrence of much less than 10%, particularly for those receiving radiation and/or hormonaltherapy.Furthermore,forthosereceivingextendedhormonal therapy such as those treated on MA.17R where the median age was 65.1 years at the time of randomization (4.5-6.0 years after starting aromatase inhibitor [AI] therapy and nearly 80% of women received tamoxifenpriortoAI),lessthan1%ofwomendevelopedipsilateralbreast events at 6.3 years. 52 Interestingly, approximately half of patients treated on study had node-positive breast cancers with an anticipated higher locoregional recurrence risk over time.
Risk for Contralateral Breast Cancer in Breast Cancer Survivors
The risk for contralateral breast cancer (CBC) for older survivors of breast cancer is even less defined than ipsilateral risk. In general and across age groups, the risk for CBC for those with a history of one cancer ranges from 2% to 11% over time, approximately 2 to 6 times the general population risk for developing a first cancer. 53 In a review of relevantstudies,theincidencerateforCBCwasreportedtobe4to8cases per 1000 person-years, with a lower risk with increasing age. 53 and others have also shown a decrease in risk for CBC with increasing age. 54 Of note, the development of CBC in the Danish study 11 was independent of time from a patient's first cancer across all ages, with steady rates over 10 years of follow-up. Information can also be gained by examining outcomes of large adjuvant hormonal therapy trials such as the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial 55 where the median age at randomization was 64 years. At a median follow-up of 120 months (and a median age of 72 years), approximately 3% of patients taking hormonal therapy developed CBC. 56 Results from the ATAC cohort are likely generalizable to the majority of older patients seen in practice who have ER-positive tumors and who are taking hormonal therapy, with an associated risk reduction for both ipsilateral and contralateral events. These collective data suggest that older patients, and particularly those taking endocrine therapy, have a 3% to 5% chance of developing CBC during the 10 years after initial diagnosis, which is similar to the general population risk of 1 of 27 (3.7%) 6 for developing a first cancer from ages 70 to 80 (though it is important that risks for ipsilateral in-breast events in survivors are also accounted for when determining overall risk). Furthermore, for those in the MA.17R trial, 52 the risk for CBC in 1918 study participants was very low at a median follow-up of 6.3 years regardless of treatment assignment, with CBC occurring in 1.4% of women taking extended letrozole and 3.2% for those assigned to placebo. 52, 57 Tumor biology also plays a role in the risk of CBC for older survivors of breast cancer. For women ages 70 to 74 years at first diagnosis, those with an ER-positive first cancer have an incidence rate of 0.37 (per 100/y; 95% CI, 0.33-0.41), while those with an ER-negative first cancer have an incidence rate of 0.55 (per 100/y; 95% CI, 0.47-0.73), likely owing to the risk reduction provided by hormonal therapy. 54 
Benefits and Harms of Surveillance Mammography in Older Survivors of Breast Cancer
Once treatments are optimized, the risk of developing in-breast events is quite low in older survivors of breast cancer. Furthermore, some of these in-breast events will be in situ cancers only, where treatments have not shown to improve breast cancer mortality. 58 Consequently, the low risk of localized recurrences combined with the increasing comorbidity (and competing causes of mortality) in this population call into question the benefit of surveillance mammography. This may be particularly relevant for those with an initial diagnosis of in situ disease, where the risk of death from breast cancer approximates that of the generalpopulation. 58 Itislikelythatsurveillancemammographyamong women with primary in situ disease may be of even lower benefit than that for women with invasive cancer. Quantifying the benefits of surveillance testing without prospective data are very challenging. Studies have suggested ongoing benefit but are limited in interpretation because of the biases inherent to retrospectivemedicalrecordsorclaims-baseddata,wheresurvivalbenefits of screening may be significantly confounded by the fact that healthy older survivors of breast cancer are more likely to undergo surveillancemammographythanlesshealthyoldersurvivorsofbreastcancer and are thus more likely to survive longer. In a study of mammographyandsurvivalamong1846breastcancersurvivors65yearsorolder with stage I or II breast cancer, each additional surveillance mammogram was associated with a 0.69-fold decrease in the odds of breast cancer mortality (95% CI, 0.52-0.92). 59 However, this study was likely substantially confounded by the excellent health of women undergoing surveillance imaging. 59 A similar study also demonstrated mortalitybenefitsofsurveillancemammographywithincreasingageandfound that the benefits of mammography were consistent even beyond the first 5 years after a diagnosis. 60 Neither of these studies addressed the 34 Furthermore,giventhecomorbidity present in many older patients and the fact that many will die of nonbreast cancer causes, [3] [4] [5] overdiagnosis and the ensuing overtreatment are even more significant than in younger patients. [27] [28] [29] [30] [31] [32] Can We Ever Stop Surveillance Mammography in Older Survivors of Breast Cancer?
Given the lack of prospective and randomized data available, it is challenging to know which older patients, if any, might derive benefit from surveillance mammography. With increasing recognition of the role of functional rather than chronological age, it is difficult to place age cutoffs for recommendations that are meaningful for both healthy and frail patients. However, the available data allow some conclusions to be drawn. First, increasing age is consistently associated with a lower risk of in-breast events, and this risk is further reduced by hormonal therapy and/or radiation. Second, there is a consistent suggestion that rates of bilateral in-breast events are low Reassess surveillance plan as appropriate a To be used as a framework for discussion with patients; this is not intended as a one-size-fits-all approach. b Consider biennial examinations in those felt to be at lower risk (ie, small, lower-risk tumors, those on endocrine therapy). c For example, Known or suspected genetic mutation, history of positive margins, high risk for bilateral breast events per provider discretion. Because cancer survivors may have a higher risk of breast cancer than women in the general population, they may benefit more; however, any mortality benefits of mammography decrease with increasing age Potential harms of screening and surveillance
Potential harms include false positive tests, unnecessary biopsies, over-diagnosis (finding cancers that would never become clinically significant in a patient's lifetime), and lack of mortality benefit [27] [28] [29] [30] [31] 34, 62 Harms are not well studied in the surveillance setting but extrapolated from screening literature Life expectancy and patient/provider preferences One's comorbidity, functional status, frailty, and life expectancy will impact how much a patient benefits from mammography
Women with a shorter life expectancy will benefit less from mammography Life expectancy should be approximated when making decisions about mammography (Table 3) Reassurance Patients should be reassured that stopping mammography does not reflect "giving up on them" as they age, but simply approaching their follow-up care in a thoughtful way that prioritizes benefits, risks, and concerns but persist over time. Given this, the timing of mammography cessation should not be specifically dictated by the time from diagnosis. However, as patients age and the probability of dying from breast cancer decreases, [3] [4] [5] increasing time from diagnosis will affect or lower the breast cancer mortality benefits of screening. It is impossible to derive a one-size-fits-all surveillance approach across all older patients with varying comorbidity and functional status. Although it is ideal to prospectively study the effect of surveillance mammography for this population, it is unlikely that we will ever have large-scale, prospective clinical trials that will optimally answer these questions for older survivors of breast cancer. Despite these challenges, it may still be possible to develop some consensus on how to tailor recommendations.
A Starting Point?
The NCCN Older Adult Oncology Guidelines 24 were recently updated toincluderecommendationsaboutsurveillancemammographyinolder survivors of breast cancer, stating that risks and benefits should be discussed, decisions should be individualized, and that patients with a life expectancy of less than 5 years are unlikely to benefit from ongoing mammography (Table 1) . Here, we aim to build upon these recommendationsandsuggestamorecomprehensiveframeworktofacilitatedialogue with patients. Although not specifically validated for breast cancer survivors, we suggest estimating life expectancy using standard life tables 24,34 (Table 2) or newer tools that incorporate health status, such as ePrognosis, 36 and we recommend the following surveillance approach and talking points ( Table 2 and Table 3 ): In recently diagnosed older patients, obtain a mammogram 6 to 12 months after local treatment to establish a baseline for future comparisons. From there, recognizing the slightly increased risk for new primary cancers and a potential clinical benefit of surveillance mammography in survivors beyond that seen in screening populations, we suggest that healthy 70-to 80-year-old survivors of breast cancer have annual or biennial mammography, similar to the ACS and USPTSF general screening recommendations. Biennial mammography would aim to maintain the benefits of surveillance while minimizing the potential harms of mammography and would allow patients to ease into a less rigorous surveillance program over time. Once patients are older than 80 years (where average life expectancy is <10 years) 35 or if patients have advanced comorbidity at any age with a life expectancy of less than 5 years, 37,60 the benefit of surveillance imaging is likely minimal, and we recommend cessation of routine surveillance mammography. We fully recognize the limitations in applying this framework to all patients but suspect these recommendations could apply to most women. However, if a woman enjoys extraordinary health at age 80 years and has a life expectancy more than 10 years and strongly wishes to continue mammography, we support an informed decision with a focus on functional rather than chronological age. Furthermore, if a woman is perceived to be at higher risk for in-breast events because of a known genetic mutation or because of her own disease characteristics and/or treatment plan (eg, positive margins), annual surveillance is reasonable to continue for longer than the average older patient until life expectancy is less than 5 years. Conversely, women who are too frail to receive adjuvant therapy should not continue mammographic surveillance. Finally, we value and recommend regular follow-up and physical examinations, including clinical breast examinations, regardless of decisions on mammography so that clinically meaningful disease can be detected and treated as appropriate.
Conclusions
In the end, even with the absence of optimal evidence to support decisions, a unified approach is needed regarding surveillance mammography in older women. The approach we propose incorporates extrapolation of existing data and the individualized needs and wishes for older survivors of breast cancer. Discussions with breast cancer survivors about mammography should take into consideration not only the risks of developing new or locally recurrent breast cancer, but the competing medical conditions that are more likely to impact survival, similar to other treatment and screening decisions. Furthermore, priorities in follow-up care should be addressed regularly with all patients, regardless of age (Table 4) , with a focus on treating underlying comorbidities and promoting a healthy lifestyle. The limited benefits of mammography should be addressed openly with patients and the "knee-jerk reflex" for indefinite annual mammography should be reconsidered, especially as it often is linked with a false security that mammography will forever improve a patient's longevity. In addition, and perhaps most importantly, clinicians should reassure patients that stopping mammography does not reflect giving up on them as they age, but simply approaching their follow-up care in a thoughtful way that prioritizes benefits, risks, and concerns. If women understand the reasons for the recommendations, even those who are initially reluctant may agree with these recommendations over time. Finally, with the aging population and growing number of older survivors of breast cancer in coming years, 9, 65 it remains an urgent research priority to prospectively examine ways to optimize surveillance strategies and decision-making in this population.
